Results

This is a permanent results page for your analyzed data. Please save the link in your browser's address bar.

GEN3VA Reports for these tags

Sunitinib TKI

SOFT file
Title / Description Gene expression changes during resistance toward vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy in renal cell carcinoma (RCC)
Accession GSE64052
Summary This study was performed to understand the gene expression changes that accompany treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Human RCC cell lines were implanted into the flanks of nude beige mice, allowed to reach 12mm in long axis, and then treated with TKIs (sunitinib or sorafenib). Tumors were excised at 2 timepoints (prior to any therapy and at the 20mm endpoint of the study) and gene expression analysis was performed.
Organism Homo sapiens
Platform GPL570
Normalized False
Parsed SOFT file
Metadata
Differential expression method Characteristic Direction
Cutoff 500
Cell 786O
Perturbation Sunitinib
Disease Renal cell carcinoma
Relevant information Sunitinib resistant (Untreated Vs.Treated)
Visualizations
Principal Component Analysis
Hierarchical clustering
External Links and Downloads
Gene lists Enrichr L1000CDS2 PAEA
Up
Down
Combined